3rd annual Expert Academy for Management of Thrombosis (EACMT)
‘When Art meets Science…’
The Kunsthal museum, located on the campus of the Thorax Center – Erasmus Medical Center Rotterdam, is the location of the 3rd annual Expert Academy for Management of Thrombosis (EACMT). Two days to discuss and share knowledge about advances in the care of patients with at risk thromboembolic complication, e.g. atrial fibrillation (AF).
This scientific program was developed by clinicians for clinicians. For this year’s event, an international faculty of prominent clinician scientists will ensure and exciting exchange of knowledge and experience, combining academic presentations, open discussion as well as ‘Live Cases’ to educate, motivate and inspire participating cardiologists. Updates and new development on managing patients at risk for thrombosis using oral anticoagulants to prevent strokes and thromboembolic complications will be shared and discussed.
The direct oral anticoagulants (DOACs) are now considered the preferred therapeutic option for most AF patients, and only limited use of the traditional vitamin K antagonist such as warfarin still exists. Their ease of use, as well as improved efficacy and safety, compared to vitamin K antagonists, have been demonstrated in large randomized clinical trials, translated into updated international guidelines.
The speakers invited to join you in this symposium will present and discuss the rationale of the expanded role of DOACs for managing AF patient’s increased risk for strokes and thromboembolic complications. The expert EACMT faculty will demonstrate the standard protocols of managing those patients pre- and post-stroke. Additionally, the symposium will discuss the latest guidelines and the benefits of DOACs in patients with coronary and peripheral arterial disease, with venous thromboembolism, and with cancer.
A perspective from cardiologists, as well as neurologists and internists, will give you a better understanding of the mechanisms of action as well as insights into which patients are most likely to benefit. Where evidence is absent or in whom alternative options are required, will be debated as well; discussing the gaps in our current knowledge on the use of DOACs, as monotherapy or what we can expect if DOACs are combined with antiplatelet agents.
A summary of the topics that will be discussed:
- Update on recent clinical trials as well as guidelines
- How to optimally manage patients:
- Elderly
- Women
- Frail
- Impaired renal function
- Undergoing TAVR
- Venous thromboembolism
- Coronary and peripheral artery disease
- Real-world data based on extensive clinical registries
- Gaps in current knowledge and understanding of DOACs in clinical practice
An essential part of this year’s educational experience will be a life TAVR case broadcasted from the Thorax Center Cath lab to the audience in the Kunsthal. Explained and commented by the head of the Thorax Center Cath lab team.
What changes can we expect in our cardiology practice? The rapid developments in IT, technology, devices, and apps has become a new area of interest. The European Society of Cardiology has recently introduced E-cardiology as a specialized field of interest covering these developments. E-cardiology aims to address the rapidly expanding choices and challenges of IT-related technologies. New wearable device, artificial intelligence (AI) and imaging technologies are being developed at an incredible speed. To highlight some of the exciting new modalities, available in today’s cardiology practice as well as innovations we can expect in the near future, will be the theme of the closing session of this year’s 2020 EACT in the Thorax Center Rotterdam.